Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer
Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092 Authors: Yael Read More
MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data
Publication: JNCI Cancer Spectrum, August 2025 Authors: Brufsky et Read More
Personalized Neoadjuvant Strategy Using 70-Gene Assay To Increase Breast-Conserving Surgery in ER+/HER2– Breast Cancer
Publication:NPJ Breast Cancer, 20 June 2025 Authors: W. Han, Read More
Clinicopathologic and Molecular Characterization of Low-Grade, Early-Stage, and HER2-Positive Invasive Breast Carcinoma
Publication: American Journal of Clinical Pathology, 2025, Vol. 163, No. Read More
Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer
Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Read More
Association of MammaPrint and Clinical Outcomes by Race Among 5000 Individuals With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Publication: ASCO® 2025 Authors: Erin Cobain, Priyanka Sharma, Kent Read More
Molecular Insights Into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint Genomic Subtypes
Publication: ASCO® 2025 Authors: Laila Samiian, Adam Brufsky, Sahra Read More
Association of ImPrintTN Signature With Survival Outcomes by Race in Basal-Type Triple Negative Breast Cancer
Publication: ASCO® 2025 Authors: Priyanka Sharma, Shane R. Stecklein, Read More
The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis
Publication: ESMO Breast Cancer 2025 Authors: Brufsky, et al. Read More
Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting
Publication: ASBRS 2025Authors: Thompson et al.Title: Real World Evidence of Read More
